Alzheimer's Disease: Targets for New Clinical Diagnostic and Therapeutic Strategies

Overview

In recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer?s disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments. Alzheimer?s Disease: Targets for New Clinical, Diagnostic, and Therapeutic Strategies provides a detailed synopsis of the current state of the art of diagnostics and therapeutics and identifies emerging technologies and molecules that show promise in the ...

See more details below
Other sellers (Hardcover)
  • All (8) from $93.65   
  • New (5) from $112.46   
  • Used (3) from $93.65   
Sending request ...

Overview

In recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer’s disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments. Alzheimer’s Disease: Targets for New Clinical, Diagnostic, and Therapeutic Strategies provides a detailed synopsis of the current state of the art of diagnostics and therapeutics and identifies emerging technologies and molecules that show promise in the management and treatment of AD.

With contributions from experts drawn from academia, clinical practice, and the biotechnology and pharmaceutical industries, the book explores:

  • The basis of AD and the role of Aβ oligomers in development of disease
  • Existing and emerging in vitro biomarker-based methodologies for the diagnosis of AD, focusing on genetic, biochemical, and conformational strategies
  • In vivo imaging diagnostic approaches
  • Evolving diagnostic criteria, health regulatory guidelines, biomarkers in clinical trials, and available and emerging therapies
  • Recent progress in small-molecule disease-modifier drug discovery efforts for AD, specifically in the areas of Aβ, tau, and emerging neuroprotective/neurorepair approaches
  • How a case study of AD raises issues regarding clinical and pathologic criteria, risk factors, and the amyloid hypothesis
  • The molecular conformational factors that govern the pathogenicity of aggregating proteins, and how these factors could represent new targets for disease-modifying therapies
  • The latest epidemiological, pathological, biochemical, and behavioral studies that may shed some light on the risk of developing AD and similar dementias after traumatic brain injury

Examining current hypotheses and suggesting possible new approaches to therapeutic clinical applications, this volume paves the way for a robust pipeline of therapeutics to combat not only AD, but a whole host of other neurodegenerative diseases.

Read More Show Less

Product Details

  • ISBN-13: 9781439827086
  • Publisher: CRC Press
  • Publication date: 5/11/2012
  • Series: Frontiers in Neuroscience Series , #50
  • Pages: 298
  • Product dimensions: 6.10 (w) x 9.30 (h) x 0.90 (d)

Meet the Author

Renee D. Wegrzyn obtained her PhD in applied biology from the Georgia Institute of Technology where she studied the propagation of prion proteins in model systems. Dr. Wegrzyn was awarded an Alexander von Humboldt Research Fellowship for her postdoctoral studies to investigate de novo protein folding at the ribosome. She applied her expertise in protein folding to the challenge of developing in vitro diagnostics for neurodegenerative diseases—including Alzheimer’s and prion diseases—as a group leader at Adlyfe, Inc. She is currently a scientific and technical consultant for the Department of Defense.

Alan S. Rudolph is currently a member of the senior executive service and director of Biological and Chemical Technologies for the Defense Threat Reduction Agency. He was previously chief executive officer at Adlyfe Inc., an amyloid diagnostic and biomarker company, chief of Biological Sciences at the Defense Advanced Research Projects Agency, and director of Research at the Naval Research Laboratory. He has over 90 publications in diverse areas in biophysics of cryobiology and anhydrobiosis, lipid and protein self-assembly, liposome science and technology, and tissue and cellular engineering. He has a PhD in zoology from the University of California at Davis and an MBA from the George Washington University.

Read More Show Less

Table of Contents

The Amyloid β-Protein and Alzheimer’s Disease; David B. Teplow, Mingfeng Yang, Robin Roychaudhuri, Eric Pang, Tien-Phat Huynh, Mei-Sha Chen, and Shiela Beroukhim

Emerging Principles and Biomarkers in In Vitro Diagnostics for Alzheimer’s Disease; Renee D. Wegrzyn and Alan S. Rudolph

Imaging Biomarkers for Diagnosis, Prognosis, and Treatment of Alzheimer’s Disease; Daniel M. Skovronsky and Giora Z. Feuerstein

The Current Status of Alzheimer’s Disease Treatment: Why We Need Better Therapies and How We Will Develop Them; Krista L. Lanctôt, Ida Kircanski, Sarah A. Chau, and Nathan Herrmann

New Small Molecule Drug Discovery for Alzheimer’s Disease; Kangning Liu, Minhua Zhang, and Guhan Nagappan

Alzheimer’s Disease: Clinical Aspects; R. Scott Turner

Pathogenic Protein Strains as Diagnostic and Therapeutic Targets in Alzheimer’s Disease; Lary C. Walker, Rebecca F. Rosen, and Harry LeVine III

Traumatic Brain Injury in the Development of Alzheimer’s Disease: Risk Factors, Diagnosis, and Treatment Strategies; Mark P. Burns

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)